Skip to main content


We're creating a new version of this page. See preview

  • Research article
  • Open Access

Dietary nucleotide improves markers of immune response to strenuous exercise under a cold environment

  • 1Email author,
  • 1,
  • 2,
  • 2,
  • 3,
  • 3 and
  • 1
Journal of the International Society of Sports Nutrition201310:20

  • Received: 14 December 2012
  • Accepted: 27 March 2013
  • Published:



Strenuous exercise has been classically associated to immune-suppression and consequently to an increased risk of infections, especially at the upper respiratory tract. The administration of dietary nucleotides has been demonstrated useful to maintain the immune function in situations of stress and thus could be an appropriate strategy to counteract the decline of the immune function associated to strenuous exercise. The aim of the present study was to asses the impact of a specific nucleotide formulation (Inmunactive®) on the markers of immune function of athletes after a heavy exercise bout under cold conditions.


Twenty elite male taekwondo athletes were randomly divided into two groups of 10 subjects that were supplemented with placebo (P) or Inmunactive (I) at 480 mg/day during 30 days. At baseline (day 0) and after 4 wk of supplementation (day 30) each subject undertook an exhaustion exercise test using a cycloergometer. Skin temperature, core temperature, heart rate, lactate concentration and rating of perceived exertion (RPE) were recorded during the test. Blood and saliva samples were obtained before and after each exercise test for determination of blood cell concentrations, PHA-stimulated lymphocyte proliferation (PHA-LP) and salivary immunoglobulin A (SIgA).


Exercise tests induced neutrophilia and reduction in lymphocyte blood counts on day 0 and on day 30 in both groups. However, the I group exhibited a faster recovery from the lymphopenic response than the P group, so that lymphocyte levels were higher after 150 min (P < 0.0028). Furthermore, the lymphoproliferative response was modulated by nucleotide supplementation, since it was higher in the I group on day 30 despite an almost significant (P < 0.06) exercise-evoked decrease at baseline.


These findings suggest that supplementation with a nucleotide-based product for 4 weeks could counteract the impairment of immune function after heavy exercise.


  • Exercise
  • Dietary nucleotides
  • Lymphocyte proliferation


Epidemiologic studies show that, while moderate activity may enhance immune function above sedentary levels, acute bouts of prolonged high-intensity exercise impair immune function and are a predisposing factor to upper respiratory tract infections (URTI) [13]. Many studies have reported that some aspects of immune function, such as lymphocyte proliferation, or of secretory immunoglobulin A (IgA) concentrations in mucosal surfaces, are temporarily impaired after acute bouts of prolonged, continuous heavy exercise [1, 47]. The elite athletes training requires repeated bouts of strenuous exercise in order to compete at the highest levels. Susceptibility to minor infections as a result of intensive endurance training is obviously a concern for athletes, as it is generally recognized that those minor infections result in a drop in exercise performance, interfere with the training program [8], and have been associated with the development of persistent fatigue [9]. Immune impairment has been associated to increased levels of stress hormones during exercise resulting in the entry into the circulation of less mature leukocytes from the bone marrow [3]. During exercise athletes are exposed to multiple stressors such as physical, psychological and environmental. Exposure to a cold environment affects the immune function, specially the lymphoproliferative responses [10]. Consequently, it has been demonstrated that vigorous exercise in cold temperatures is associated to increased susceptibility to URTI [11, 12] even above what is observed with physical exercise alone [13].

Nucleotides are low molecular weight intracellular compounds, which play key role in nearly all biochemical processes [14]. As nucleotides can be synthesized endogenously they are not essential nutrients. However, under situations of stress, dietary nucleotides have been reported to have beneficial effects upon the immune system [14, 15]. Although the molecular mechanisms by which dietary nucleotides modulate the immune system are practically unknown, it has been demonstrated that nucleotides influence lymphocyte maturation, activation and proliferation [1618]. Likewise, they affect the lymphocyte subset populations [19, 20], macrophage phagocytosis [17], immunoglobulin production [18, 21], and delayed hypersensitivity as well as allograft and tumour responses [15, 17]. Consequently, in several studies nucleotides supplementation has been shown to reverse the immune suppression associated to stress situations [22, 23]. However, data available on endurance exercise trials is scarce. In controlled studies, it has been demonstrated that dietary nucleotides attenuates the fall of salivary IgA (SIgA) [24], the increase in salivary cortisol [25] and the decrease in the lymphocyte proliferative response [26] after the strenuous exercise. Nevertheless, aside from this study, there is no data available from prospective, double-blind, placebo-controlled studies, on the effects of nucleotide supplementation on the markers of immune response after strenuous exercise in a cold environment.

The aim of the present study was to test the impact of a specific nucleotide formulation (Inmunactive®, Bioiberica, Spain) on the immune function of athletes after a heavy exercise bout in cold conditions.



Twenty elite male taekwondo players were recruited at the Centre d’Alt Rendiment (CAR) St. Cugat to participate in this study. Before being accepted to participate in the investigation, each subject performed a complete medical examination that included a medical history and resting ECG to screen for any medical problem that would contraindicate their participation in the study. The subject’s general physical characteristics were: 21.4 ± 6.3 years, 178.1 ± 8.5 cm, 73.86 ± 12.6 kg, 12.53 ± 3.2% percent body fat and 46.59 ± 5.7 ml · kg-1 · min-1 maximal oxygen uptake (VO2max).

This study was conducted according to the guidelines of the Declaration of Helsinki for Research on Human Subjects 1989 and was approved by the local Ethics Committee of the Consell Català de l’Esport (Generalitat de Catalunya).

Research design

Two weeks before the first test, all the subjects performed a cycling maximal incremental test to determine their VO2max. Oxygen consumption was measured using a computerized metabolic cart (Master Screen CPX, Erich Jaeger, Wuerzburg, Germany), and the corresponding Watts at 60% (W1) 70% (W2) and 90% (W3) of VO2max were calculated by linear interpolation. For the exercise test, subjects reported to the CAR laboratory at 8 a.m. after an overnight fast. Dry nude body weight was measured before and after the experiment following the subject had emptied the urinary bladder. The rate of dehydration was calculated by dry nude weight difference before and after testing. A saliva sample and a 8.5 mL blood sample were taken after a 10 min supine rest. Subjects were required to use the same clothes in both exercise sessions. The subjects entered into the climatic chamber, adjusted a cycle ergometer, placed the chest Hr transmitter and skin thermistors and undertook an exhaustion exercise test at work corresponding to W1 for 10 min, W2 for 20 min and W3 until fatigue in a climatic chamber adjusted at -3°C. Heart rate (Hr) was registered at rest and every 5 min during the exercise test using a chest Hr monitor (Polar Electro Inc, Kempele, Finland). Every 10 min a 20 μL blood sample was obtained from the ear lobule to analyze lactate concentration ([La]) (Dr. Lange® Berlin, Germany). Rate of perceived exhaustion (RPE) was recorded every 10 min during the test using the Borg scale [27]. Skin and core temperature (Tc) were continuously recorded during the exercise test. Tc was measured by intestinal pill system (Cor-Temp 2000®, HQInc, Palmetto, Florida, EEUU). The ingestible pill was swallowed approximately eight hours before the test to ensure passing into to gastrointestinal tract and Tc collected for analysis at rest and every 5 minutes during exercise, and after 5 minutes of recovery into the climatic chamber and was recorded using a telemetric sensor according the procedure described by Byrne [28]. Skin temperature was measured continuously with 4 skin thermistors (CCI® PT-100 W/0°C, Barcelona, Spain) placed in to the parasternal chest-side, mid arm, mid thigh and medial calf. The mean skin temperature (Tsk) was calculated according to a Ramanathan formula [29] and collected for analysis at rest, every 5 minutes and after 5 minutes of recovery inside the climatic chamber. The average body temperature (Tm) was calculated using the formula Tm = 0, 79 × Tc + 0, 21 × Tsk[30]. Saliva samples were collected at 150 min after the end of the exercise test and blood samples were collected at 30 min, and 150 min for complete blood count (CBC) and at 24 h for the PHA-stimulated lymphocyte proliferation (PHA-LT) test.

Dietary supplementation

Subjects agreed to avoid the use of large-dose vitamin/mineral supplements (>100% of recommended dietary allowances), herbs, and medications known to affect immune function during the entire 31-d study. Subjects recorded food intake in a 7-d food record before the first exercise test session and thorough the study. The food records were analyzed using a computerized dietary assessment program (ADN®, Barcelona, Spain). During orientation, a dietician instructed the subjects to follow a balanced diet and to no change habits during the study period.

After the first exercise test, each subject was randomly assigned to either the Inmunactive® (I) or placebo (P) group. Inmunactive® (Bioiberica, Barcelona, Spain) is a food supplement containing a mixture of free nucleotides (cytidine 5’-monophosphate, uridine 5’-monophosphate, adenosine 5’-monophosphate and guanosine 5’-monophosphate). The content of free nucleotides is 49.38 g/100 g. The commercial batch used for the study was D-01. The nucleotide content in the commercial batch used for the study (D-01) was confirmed analytically using a Waters 2695 (Milford, MA) HPLC system with a photodiode array extended λ detector Waters 2488.

Experimental products were provided under double-blind procedures. For blinding, a computer generated randomization number was assigned to unmarked boxes containing either Inmunactive® or placebo. The randomization code was maintained by the sponsor and concealed from the study site. Treatment allocation depended only on the time sequence in which patients entered the study, thus minimizing selection bias. All study-related case report forms recorded only the randomization number with unblinding only after the completion of the study or analyses.

Subjects in the nucleotide group (I) were treated with Inmunactive® at a dose of 972 mg · day-1 (2 capsules/day) for 30 days, while subjects in the placebo group (P) were treated during the same period with 2 capsules · day-1 containing excipient (microcrystalline cellulose).

Compliance was recorded during the study within the food records and monitored before the second exercise test.

Subjects agreed to maintain a steady training status which was recorded during the intervention period. After 30 days, subjects returned to the laboratory to undertake the second exercise test as described previously.

Saliva analysis

Saliva production was stimulated by chewing a sterile cotton swab (Salivette; Sersted, Vümbrecht, Germany) during 60 seconds, and saliva was separated from the cotton by centrifugation at 2000 rpm × 5 minutes. Saliva samples were frozen at -80°C and stored until the end of the study period. SIgA concentration was analyzed using nephelometric quantification (BN™ II System, Siemens, Deerfield, IL, USA) according to the validated manufacturer protocol. Results were expressed in mg/L.

Blood analysis

Blood samples (3.5 mL) were taken from the antecubital vein and collected in EDTA tubes. CBC was analyzed using the impedance system Abacus Junior® (Tecil, Barcelona, Spain).

Phytohemagglutinin-stimulated lymphocyte proliferation

Blood samples (4 mL) were collected in heparinised tubes to analyze the lymphocyte proliferation rate. The mitogenic response of lymphocytes was determined in whole blood culture using phytohemaglutinin (PHA) at an optimal dose previously determined by titration experiments. Heparinized venous blood was diluted 1:10 with complete media consisting of RPMI-1640 supplemented with 5% heat-inactivated fetal bovine serum, penicillin, streptomycin, sodium pyruvate, L-glutamine, A2-mercaptoethanol, and Mito + ™ Serum Extender (Cat. no. 355006; Becton Dickinson Immunocytometry Systems, San Jose, CA). PHA was prepared in RPMI-1640 media at a concentration of 1 mg/mL and was then further diluted with complete media to the optimal working concentration (6.25 μg/mL). A 100 μL aliquot of the diluted blood was dispensed into each of triplicate wells of a 96-well flat-bottom microtiter plate. To each well, 100 μL of the appropriate mitogen concentration was added. Control wells received complete media instead of mitogen. After 72 h incubation at 37°C and 5% CO2, the cells were pulsed with 1 μCi of [3H]-thymidine (New England Nuclear, Boston, MA) prepared with RPMI-1640. After pulsing, cells were incubated for an additional 4 h before harvesting. The radionucleotide incorporation was assessed using a Wallac 1409 RackBeta liquid scintillation counter (LKB Wallac, Inc., Gaithersburg, MD) with the results expressed as experimental minus control counts per minute (cpm).

Statistical analysis

Data were subjected to analysis of variance according to the general linear model (GLM) procedure of the Statistical Analysis System software package version 6.11 (SAS Institute, Cary, NC, USA). Repeated measures analysis of variance with time and treatment as the within-subject factor was used to analyze blood count, salivary IgA and PHA-stimulated lymphocyte proliferation over time using the model MIXED-type TOEP of SAS, and LSMEANS follow-up test was used for comparisons of means. A two-tailed P-value of < 0.05 was considered significant.


Basal subject characteristics and performance data for the 20 subjects are summarized in Table 1. No significant differences were found between groups for age, body composition, or maximal performance measures. The mean temperature and% of humidity in the climatic chamber were -2.5 ± 1.4°C and 67 ± 7.3% for day 0, and -2.3 ± 2.8°C and 60.72 ± 5.0% for day 30. The exercise test had an average duration of 47.3 ± 5.3 minutes. Tsk, Tc and Tm increased during the exercise test and reached a physiological steady state. Figure 1 and Table 2 shows that thermoregulation mechanisms were not compromised during the exercise tests and weight loss was less than 1% (0.77% and 0.71%).
Table 1

Subjects characteristics and performance at baseline




Age (yr)

22.8 ± 5

21.9 ± 3

Body mass (kg)

70.7 ± 4.7

75.8 ± 3.25

Body composition (% fat)

11.6 ± 3.5

9.5 ±3.8

VO2max (mL · kg-1 · min-1)

45.8 ± 5.3

47.3 ± 7.0

VO2max = maximal oxygen uptake. Values are presented as means ± SE (n = 10).

No differences between groups were detected.

Figure 1
Figure 1

Mean temperature and heart rate during exercise before and after 30 days of supplementation. Values are means ± SE (n = 10). P = Placebo; I = Inmunactive. Tm = Mean temperature; HR = Heart Rate.

Table 2

Maximal physiological and performance values on exercise tests before and after 30 days of supplementation


Day 0 Inmunactive


Day 30 Inmunactive


Skin temperature (°C)

29.1 ± 0.4

29.4 ± 0.3

30.4 ± 0.6

29.4 ± 0.7

Core temperature (°C)

38.5 ± 0.1

38.5 ± 0.1

38.5 ± 0.1

38.2 ± 0.1

Heart rate (bpm)

176 ± 3

179 ± 3

171 ± 4

171 ± 3

Lactate (mM)

10.1 ± 0.9

9.9 ± 1.1

8.7 ± 0.6

7.7 ± 1.4

Borg scale

18.8 ± 0.1

18.6 ± 0.2

18 ± 0.4

17.9 ± 0.5

Values are means ± SE (n = 10). No significant differences across time within a group treatment or between groups at specified time point were detected.

On day 0 the average HRmax of all the participants reached 177 ± 2 bpm corresponding to 96% of the HRmax determined in the maximal incremental test (Table 2). On day 30 the average HRmax showed a decreasing trend (171 ± 2 bpm; P = 0.06). Maximal lactate concentration tended to be lower (P = 0.09) and maximal RPE was significantly lower (P = 0.03) on day 30 in comparison with day 0. No differences between treatment groups were detected in performance parameters, except for RPE recorded during the exercise test on day 30. Thus values were lower for I compared to P group at 10 min (9.9 ± 0.5 vs. 11.2 ± 0.7; P = 0.0496), 20 min (13.2 ± 0.6 vs. 14.7 ± 0.3; P = 0.0238) and 30 min (15.2 ± 0.6 vs. 16.6 ± 0.4; P = 0.0347) but not at the end of the test (40 min; 17.2 ± 0.5 vs. 17.6 ± 0.4; P = 0.4582). The maximum Borg value was not different between groups (Table 2), because all the participants reached exhaustion before finishing the test.

Seven-day food records before the exercise test revealed no significant group differences in energy or macronutrient intake. Energy intake was 2195 ± 527 Kcal, containing 247 ± 66 g of carbohydrate, 88.4 ± 24.1 g of fat and 100 ± 25 g of protein for all subject combined. Similarly, no changes in food intake were recorded thorough the study period.

To avoid the influence of possible changes in plasma volume caused by exercise, CBC was adjusted following the methodology proposed by Dill and Costill [31]. There was a significant effect of time during the exercise test (basal, 30 min, 150 min) for total leukocyte, neutrophil an lymphocyte counts (P < 0.05) (Table 3), namely an increase in total leukocyte and neutrophil counts at 150 min after exercise and a decrease in lymphocyte counts 30 and 150 min after exercise. However no differences between groups or across exercise tests (day 0 and day 30) were detected in the pattern of response except for the lymphocyte counts. Thus on day 30 the I group, supplemented with nucleotides, did experience a decrease in lymphocyte counts at 30 min compared to the basal values but a total recovery was registered at 150 min, while the placebo group stayed low and was significantly reduced compared with the I group (P = 0.0028).
Table 3

Blood count during exercise tests before and after 30 days of supplementation


Day 0 Inmunactive


Day 30 Inmunactive


Total leukocytes (109 · L-1)



6.38 ± 0.53b

6.10 ± 0.47b

7.00 ± 0.71b

5.25 ± 0.44b

30 min

6.34 ± 0.76b

6.72 ± 0.93b

6.83 ± 0.74b

5.66 ± 0.72b

150 min

10.45 ± 1.19a

9.86 ± 1.03a

10.36 ± 0.86a

8.32 ± 0.96ª

Neutrophils (109 · L-1)



3.69 ± 0.35c

3.27 ± 0.41b

4.06 ± 0.43b

2.98 ± 0.38b

30 min

4.30 ± 0.70b

4.65 ± 0.87b

4.30 ± 0.54b

3.83 ± 0.70b

150 min

8.06 ± 0.89a

7.80 ± 1.01a

7.27 ± 0.59a

7.17 ± 1.05ª

Lymphocytes (109 · L-1)



2.03 ± 0.14ª

2.03 ± 0.13ª

2.12 ± 0.22ª

1.73 ± 0.12ª

30 min

1.37 ± 0.09b

1.39 ± 0.12b

1.77 ± 0.17b

1.44 ± 0.09b

150 min

1.68 ± 0.11b

1.43 ± 0.11b

2.27 ± 0.37ª*

1.50 ± 0.07ab

Values are means ± SE (n = 10). Different superscripts indicate significant differences across time within a group treatment. An asterisk indicates significant differences between groups at specified time point (P < 0.05).

There was no effect of time (basal or 150 min), exercise test (day 0 or day 30) or treatment group on salivary IgA concentration (P > 0.05) (Table 4). Similarly, there was no significant effect of exercise on the lymphoproliferative response, although an almost significant decrease was observed in the I group at baseline, i.e. prior to treatment (P < 0.06, Table 4). This resulted in a lower lymphocyte proliferation in the treated group. Despite this apparently higher susceptibility to exercise-evoked depression in the lymphoproliferative response, the I group exhibited a significantly higher proliferation after the 30 day supplementation period, indicating a full reversal of this tendency. In keeping with this, the statistical analysis showed a significant day*group interaction (P = 0.0045).
Table 4

Salivary IgA and PHA-Stimulated lymphocyte proliferation during exercise tests before and after 30 days of supplementation


Day 0 Inmunactive


Day 30 Inmunactive


Salivary IgA (mg · L-1)



1.87 ± 0.38

2.59 ± 1.16

2.32 ± 0.96

2.31 ± 0.61

150 min

2.43 ± 1.06

2.13 ± 0.70

1.91 ± 0.54

1.35 ± 0.45

PHA-Stimulated lymphocyte proliferation (cpm · 1000-1)



29.3 ± 3.5

35.5 ± 4.4

29.1 ± 2.1

25.9 ± 3.9

24 h

21.4 ± 3.6

35.9 ± 53.8*

34.5 ± 5.4

20.6 ± 5.1*

Values are means ± SE (n = 10). An asterisk indicates significant differences between groups at specified time point (P < 0.05).


Scientific evidence from placebo-controlled trials of nutritional compounds having a positive enhancing effect on the immune function in the healthy population is scarce [32]. High-intensity exercise has been classically associated to immune disturbances in healthy individuals [2] and thus could be considered as a model to study the efficacy of nutritional interventions in populations during periods of immune suppression [33]. Exposure to cold environments has been claimed to elicit a stress response impacting immune cell function [10], but evidences from controlled studies are also scarce [13]. Research on the potential for dietary nucleotides to enhance the human immune response is wide but human trials are mainly restricted to critically ill patients [34] and to supplementation of infant formula [35]. To our knowledge, this is the first controlled study in which the efficacy of nucleotide supplementation has been evaluated in healthy individuals under multiple stressors such as strenuous exercise and cold environment.

The exercise protocol was designed to elicit an immune disturbance according to previously published data [4, 36]. Subjects were instructed to perform a controlled physical work corresponding to 90% of the VO2max for more than 20 minutes, in an exercise bout of more than 45 minutes in total. The described workload led to exhaustion as demonstrated by the maximum heart rate, lactate concentration and Borg values. On the second exercise test, Borg values were lower and HRmax and lactate concentration tended to be lower than in the previous exercise test, probably due to the effect of the training during the month of the trial. Levels of salivary IgA were unaffected by the exercise. Although falls in saliva IgA can occur during intense exercise [3739], levels are generally unchanged with exercise lasting less than 1 h [40] and also not affected by environmental temperature [4143], as observed in the present trial. Nevertheless, in the present trial the workload in first and second exercise tests was enough to elicit a profound leukocytosis and neutrophilia. Marked changes in blood leukocyte counts resulting from a single bout of high intensity exercise are well known and are due largely to the movement of neutrophils from the marginal pool to the circulating pool as a result of muscular action [44]. It is documented that neutrophilia depends of exercise intensity and duration [7] and also of body temperature attained during exercise [45]. Acute exercise results in a rapid increase in blood neutrophil counts likely due to demargination caused by shear stress and catecholamines [46], which is followed by a delayed neutrophilia attributed to cortisol-induced release of neutrophils from the bone marrow [46]. An increase in blood neutrophil numbers does not imply better neutrophil function, because neutrophils released as a result of acute exercise are relatively immature and consequently their degranulation and oxidative burst in response to bacterial stimulation may be reduced for many hours after the exercise bout [4749]. Acute exercise elicits characteristic transient biphasic changes in the numbers of circulating lymphocytes. Typically, a lymphocytosis is observed immediately after exercise, with numbers of cells falling below pre-exercise levels during the early stages of recovery [50]. Results obtained in this study are in total agreement with this pattern of response, with significant decreases in lymphocyte numbers detected at 30 and 150 min after exercise, except for the group supplemented with nucleotides in which a total recovery on the number of lymphocytes was detected at 150 min. Although it has been shown that dietary nucleotides stimulates the maturation of immune cells [17, 51], the rapid recovery in lymphocyte counts registered between 30 and 150 min after the exercise test, suggest a redistribution from other cell compartments.

There is considerable evidence demonstrating that exogenous nucleotides increase the proliferative response to T cell-dependent mitogens (PHA, ConA and PWM) [14, 17]. In the present study, significant differences in lymphocyte proliferation have been detected between treatment groups at 24 h after exercise. On the initial exercise test, lymphoproliferative activity was higher in the placebo group (P < 0.05), while after supplementation it was higher in the nucleotide group (P < 0.05). Interpretation of the data is hampered by the fact that values are different in the baseline test. This was probably due to the reduced sample size (10 athletes per group) and the randomized nature of the study, which resulted by happenstance (since this result is prior to intervention) in an almost significant effect of exercise in the I group. This may be interpreted to indicate a higher susceptibility of this group to depressed lymphocyte proliferation in the face of intense physical activity. This in turn would be expected to dampen, or hide, a putative effect of the nucleotide supplement in this regard. Despite this obstacle, Inmunactive effectively augmented the lymphoproliferative response in the treated group, suggesting that this is a consistent effect. Previous studies using standard lymphocyte proliferation assays have reported significant reductions in T-lymphocyte responses to mitogen after medium- and long-duration intense exercise [52], which have been suggested to explain the observed high incidence of infections in elite athletes [53, 54]. These reductions of proliferative responses have been attributed to an increase in cell death of both CD4 and CD8 T lymphocytes, rather than to decrease in mitosis rate [55]. The molecular mechanisms by which dietary nucleotides exert their effects are largely unknown, but recent findings have demonstrated that they affect the expression and activity of several transcriptional factors involved in cell growth, differentiation and apoptosis [56]. Specifically exogenous nucleotides have shown to reduce the expression and activity of the glucocorticoid receptor NR3C1, the upstream stimulatory factor USF1, NF-κB and the tumor protein p53. TP53 responds to diverse cellular stresses to regulate target genes that induce cell arrest, apoptosis and senescence [57].


Our results suggest that exogenous nucleotides may have a protective effect on the on the markers immune response of athletes after strenuous exercise. According to the recent findings, it could be hypothesized that this protection could be mediated by a preventive effect against apoptosis induced by different stress stimuli. However further studies are required to elucidate the mechanisms of action of dietary nucleotides, as well as to evaluate their potential in prevention of immune disturbances.



We would like to thank the participants that participated in this study as well as our fellow colleagues, at Centre d’Alt Rendiment (GIRSANE) who assisted with data collection. This study was funded by Bioiberica S.A. (Palafolls, Spain). All researchers involved independently collected, analyzed, and interpreted the results from this study and have no financial interests concerning the outcome of this investigation. The results from this study do not constitute endorsement by the authors.

Authors’ Affiliations

Sports Physiology Department, Centre d’Alt Rendiment (CAR-GIRSANE), Av. Alcalde Barnils 3-5, Sant Cugat del Vallés, Barcelona, 08174, Spain
Bioiberica S.A., Ctra. N-II km 680.6, Palafolls, Barcelona, 08389, Spain
Laboratory of Physical Activity Science, Universitat de les lles Balears, Ctra. Valldemossa Km 7.5, Palma de Mallorca, E07122, Spain


  1. Nieman DC: Exercise, upper respiratory tract infection and the immune system. Med Sci Sports Exerc. 1994, 26: 128-139. 10.1249/00005768-199402000-00002.View ArticlePubMedGoogle Scholar
  2. Petersen WE, Pedersen BK: Exercise and immune function – effect of nutrition. Nutrition and Immune Function. Edited by: Calder PC, Fielf CJ, Gill HS. 2002, CABI Publishing, New York, 347-355.View ArticleGoogle Scholar
  3. Gleeson M: Immune function in sport and exercise. J Appl Physiol. 2007, 103: 693-699. 10.1152/japplphysiol.00008.2007.View ArticlePubMedGoogle Scholar
  4. Pedersen BK, Bruunsgaard H: How physical exercise influences the establishment of infections. Sports Med. 1995, 19: 393-400. 10.2165/00007256-199519060-00003.View ArticlePubMedGoogle Scholar
  5. Pyne DB: Regulation of neutrophil function during exercise. Sports Med. 1994, 17: 245-258. 10.2165/00007256-199417040-00005.View ArticlePubMedGoogle Scholar
  6. Ronsen O, Pedersen BK, Øritsland TR, Bahr R, Kjeldsen-Kragh J: Leukocyte counts and lymphocyte responsiveness associated with repeated bouts of strenuous endurance exercise. J Appl Physiol. 2001, 91: 425-434.PubMedGoogle Scholar
  7. Shephard RJ, Shek PN: Effects of exercise and training on natural killer cell counts and cytolytic activity: a meta-analysis. Sports Med. 1999, 28: 177-195. 10.2165/00007256-199928030-00003.View ArticlePubMedGoogle Scholar
  8. Roberts JA: Viral illnesses and sports performance. Sports Med. 1986, 4: 298-303.Google Scholar
  9. Friman G, Ilbäck NG: Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Int J Sports Med. 1998, 19 (Suppl 3): S172-S182.View ArticlePubMedGoogle Scholar
  10. Juránková E, Jezová D, Vigas M: Central stimulation of hormone release and the proliferative response of lymphocytes in humans. Mol Chem Neuropathol. 1995, 25: 213-223. 10.1007/BF02960914.View ArticlePubMedGoogle Scholar
  11. Berglund B, Hemmingson P: Infectious disease in elite cross-country skiers: a one-year incidence study. Clinical Sports Med. 1990, 2: 19-23.Google Scholar
  12. Tomasi TB, Trudeau FB, Czerwinski D, Erredge S: Immune parameters in athletes before and after strenuous exercise. J Clin Immunol. 1982, 2: 173-178. 10.1007/BF00915219.View ArticlePubMedGoogle Scholar
  13. Lavoy EC, McFarlin BK, Simpson RJ: Immune Responses to Exercising in a Cold Environment. Wilderness Environ Med. 2011, 4: 343-351.View ArticleGoogle Scholar
  14. Gil A: Modulation of the immune response mediated by dietary nucleotides. Eur J Clin Nutr. 2002, 3 (Suppl): S1-S4.View ArticleGoogle Scholar
  15. Carver JD, Walker WA: The role of nucleotides in human nutrition. J Nutr Biochem. 1995, 6: 58-72. 10.1016/0955-2863(94)00019-I.View ArticleGoogle Scholar
  16. Gil A: New additions to infant formulas. Pediatric gastroenterology and nutrition in clinical practice. Edited by: Liftschitz C. 2001, Marcel Dekker, New York, 113-135.View ArticleGoogle Scholar
  17. Kulkarni A, Fanslow W, Higley H, Pizzini R, Rudolph F, Van Buren C: Expression of immune cell surface markers in vivo and immune competence in mice by dietary nucleotides. Transplant Proc. 1989, 21: 121-124.PubMedGoogle Scholar
  18. Gil A, Martínez-Augustín O, Navarro J: Role of dietary nucleotides in the modulation of the immune response. Neonatal hematology and immunology III. Edited by: Bellanti JA, Bracci R, Prindull G, Xanthou M. 1973, Elsevier Science, Amsterdam, 139-144.Google Scholar
  19. Buck RH, Thomas DL, Winship TR, Cordle CT, Kuchan MJ, Baggs GE, Schaller JP, Wheeler JG: Effect of dietary ribonucleotides on infant immune status. Part 2: immune cell development. Pediatr Res. 2004, 56: 891-900. 10.1203/01.PDR.0000145577.03287.FA.View ArticlePubMedGoogle Scholar
  20. Manzano M, Abadía-Molina AC, García-Olivares E, Gil A, Rueda R: Dietary nucleotides accelerate changes in intestinal lymphocyte maturation in weanling mice. J Pediatr Gastroenterol Nutr. 2003, 37: 453-461. 10.1097/00005176-200310000-00010.View ArticlePubMedGoogle Scholar
  21. Navarro J, Maldonado J, Narbona E, Ruiz-Bravo A, García Salmerón JL, Molina JA, Gil A: Influence of dietary nucleotides on plasma immunoglobulin levels and lymphocyte subsets of preterm infants. Biofactors. 1999, 10: 67-76. 10.1002/biof.5520100108.View ArticlePubMedGoogle Scholar
  22. Brunser O, Espinoza J, Araya M, Cruchet S, Gil A: Effect of dietary nucleotide supplementation on diarrhoeal disease in infant. Acta Paediatr. 1994, 83: 188-191. 10.1111/j.1651-2227.1994.tb13048.x.View ArticlePubMedGoogle Scholar
  23. Pickering LK, Granoff DM, Erickson JR, Masor ML, Cordle CT, Schaller JP, Winship TR, Paule CL, Hilty MD: Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics. 1998, 101: 242-249. 10.1542/peds.101.2.242.View ArticlePubMedGoogle Scholar
  24. Mc Naughton L, Bentley D, Koeppel P: The effects of a nucleotide supplement on the immune and metabolic response to short term, high intensity exercise performance in trained male subjects. J Sports Med Phys Fitness. 2007, 47: 112-118.PubMedGoogle Scholar
  25. Mc Naughton L, Bentley DJ, Koeppel P: The effects of a nucleotide supplement on salivary IgA and cortisol after moderate endurance exercise. J Sports Med Phys Fitness. 2006, 46: 84-89.PubMedGoogle Scholar
  26. Casajús J, Martínez-Puig D, Sánchez D, Aguiló J, Anel A, Lou J, Chetrit C: The effects of a nucleotide supplement (Inmunactive) on lymphocite proliferation after intensive exercise. Book of Abstracts of the 14th annual Congress of the European College of Sport Science (ECSS). Edited by: Loland S, Bø K, Fasting K, Hallén J, Ommundsen Y, Roberts G, Tsolakidis E. 2009, European College of Sport Science, Oslo, 129-Google Scholar
  27. Borg G: Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970, 2 (2): 92-98.PubMedGoogle Scholar
  28. Byrne C, Lim CL: The ingestible telemetric body core temperature sensor: a review of validity and exercise applications. Br J Sports Med. 2007, 41: 126-133. 10.1136/bjsm.2006.026344.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Ramanathan N: A new weighting system for mean surface temperature of the human body. J Appl Physiol. 1964, 19: 531-533.PubMedGoogle Scholar
  30. Colin J, Timbal J, Houdas Y, Boutelier C, Guieu JD: Computation of mean body temperature from rectal and skin temperatures. J Appl Physiol. 1971, 31: 484-489.PubMedGoogle Scholar
  31. Dill DB, Costill DL: Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol. 1974, 37: 247-248.PubMedGoogle Scholar
  32. Gleeson M: Can nutrition limit exercise-induced immunodepression?. Nutr Rev. 2006, 64: 119-131. 10.1111/j.1753-4887.2006.tb00195.x.View ArticlePubMedGoogle Scholar
  33. Shing CM, Peake J, Suzuki K, Okutsu M, Pereira R, Stevenson L, Jenkins DG, Coombes JS: Effects of bovine colostrum supplementation on immune variables in highly trained cyclists. J Appl Physiol. 2007, 102: 1113-1122.View ArticlePubMedGoogle Scholar
  34. Sacks GS, Genton L, Kudsk KA: Controversy of immunonutrition for surgical critical-illness patients. Curr Opin Crit Care. 2003, 9: 300-305. 10.1097/00075198-200308000-00008.View ArticlePubMedGoogle Scholar
  35. Gutiérrez-Castrellón P, Mora-Magaña I, Díaz-García L, Jiménez-Gutiérrez C, Ramirez-Mayans J, Solomon-Santibáñez GA: Immune response to nucleotide supplemented infant formulae: systematic review and meta-analysis. Br J Nutr. 2007, 98: 64-67.View ArticleGoogle Scholar
  36. Walsh NP, Gleeson M, Pyne DB, Nieman DC, Dhabhar FS, Shephard RJ, Oliver SJ, Bermon S, Kajeniene A: Position statement. Part two: Maintaining immune health. Exerc Immunol Rev. 2011, 17: 64-103.PubMedGoogle Scholar
  37. Fahlman MM, Engels HJ: Mucosal IgA and URTI in American college football players: a year longitudinal study. Med Sci Sports Exerc. 2005, 37: 374-380. 10.1249/01.MSS.0000155432.67020.88.View ArticlePubMedGoogle Scholar
  38. Gleeson M, McDonald WA, Cripps AW, Pyne DB, Clancy RL, Fricker PA: The effect on immunity of long-term intensive training in elite swimmers. Clin Exp Immunol. 1995, 102: 210-216.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Gleeson M, McDonald WA, Pyne DB, Cripps AW, Francis JL, Fricker PA, Clancy RL: Salivary IgA levels and infection risk in elite swimmers. Med Sci Sports Exerc. 1999, 31: 67-73. 10.1097/00005768-199901000-00012.View ArticlePubMedGoogle Scholar
  40. Bishop NC, Gleeson M: Acute and chronic effects of exercise on markers of mucosal immunity. Front Biosci. 2009, 14: 4444-4456.View ArticleGoogle Scholar
  41. Housh TJ, Johnson GO, Housh DJ, Evans SL, Tharp GD: The effect of exercise at various temperatures on salivary levels of immunoglobulin A. Int J Sports Med. 1991, 12: 498-500. 10.1055/s-2007-1024722.View ArticlePubMedGoogle Scholar
  42. Laing SJ, Gwynne D, Blackwell J, Williams M, Walters R, Walsh NP: Salivary IgA response to prolonged exercise in a hot environment in trained cyclists. Eur J Appl Physiol. 2005, 93: 665-671. 10.1007/s00421-004-1270-7.View ArticlePubMedGoogle Scholar
  43. Walsh NP, Bishop NC, Blackwell J, Wierzbicki SG, Montague JC: Salivary IgA response to prolonged exercise in a cold environment in trained cyclists. Med Sci Sports Exerc. 2002, 34: 1632-1637. 10.1097/00005768-200210000-00015.View ArticlePubMedGoogle Scholar
  44. Mochida N, Umeda T, Yamamoto Y, Tanabe M, Kojima A, Sugawara K, Nakaji S: The main neutrophil and neutrophil-related functions may compensate for each other following exercise-a finding from training in university judoists. Luminescence. 2007, 22: 20-28. 10.1002/bio.922.View ArticlePubMedGoogle Scholar
  45. Mestre-Alfaro A, Ferrer MD, Banquells M, Riera J, Drobnic F, Sureda A, Tur A, Pons A: Body temperature modulates the antioxidant and acute immune responses to exercise. Free Radic Res. 2012, 46: 799-808. 10.3109/10715762.2012.680193.View ArticlePubMedGoogle Scholar
  46. McCarthy DA, Macdonald I, Grant M, Marbut M, Watling M, Nicholson S, Deeks JJ, Wade AJ, Perry JD: Studies on the immediate and delayed leucocytosis elicited by brief (30-min) strenuous exercise. Eur J Appl Physiol Occup Physiol. 1992, 64: 513-517. 10.1007/BF00843760.View ArticlePubMedGoogle Scholar
  47. Peake J, Suzuki K: Neutrophil activation, antioxidant supplements and exercise induced oxidative stress. Exerc Immunol Rev. 2004, 10: 129-141.PubMedGoogle Scholar
  48. Peake JM: Exercise-induced alterations in neutrophil degranulation and respiratory burst activity: possible mechanisms of action. Exerc Immunol Rev. 2002, 8: 49-100.PubMedGoogle Scholar
  49. Robson PJ, Blannin AK, Walsh NP, Castell LM, Gleeson M: Effects of exercise intensity, duration and recovery on in vitro neutrophil function in male athletes. Int J Sports Med. 1999, 20 (2): 128-135.PubMedGoogle Scholar
  50. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P: Position statement. Part one: Immune function and exercise. Exerc Immunol Rev. 2011, 17: 6-63.PubMedGoogle Scholar
  51. Fontana A, Martinez-Augustin O, Gil A: Role of Dietary Nucleotides in Immunity. Functional Food Reviews. 2010, 3: 91-100.Google Scholar
  52. Nieman DC: Exercise, infection, and immunity. Int J Sports Med. 1994, 15 (Suppl 3): S131-S141.View ArticlePubMedGoogle Scholar
  53. Linde F: Running and upper respiratory tract infections. Scand J Sports Sci. 1987, 9: 21-23.Google Scholar
  54. Mackinnon LT: Immunity in athletes. Int J Sports Med. 1997, 18 (Suppl 1): S62-S68.View ArticlePubMedGoogle Scholar
  55. Green KJ, Rowbottom DG: Exercise-induced changes to in vitro T-lymphocyte mitogen responses using CFSE. J Appl Physiol. 2003, 95: 57-63.View ArticlePubMedGoogle Scholar
  56. Ortega A, Gil A, Sánchez-Pozo A: Exogenous nucleosides modulate expression and activity of transcription factors in Caco-2 cells. J Nutr Biochem. 2011, 22: 595-604. 10.1016/j.jnutbio.2010.05.003.View ArticlePubMedGoogle Scholar
  57. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappa-B in p53-mediated programmed cell death. Nature. 2000, 404: 892-897. 10.1038/35009130.View ArticlePubMedGoogle Scholar


© Riera et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.